Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by SimonSaysLueson Apr 01, 2024 10:07pm

330 Views

Post# 35964137

Fire side chats

Just remember folks...nuance is way smarter than our bush league pilot of a CEO. As long as the FDA blocks this trial all we are doing is lining Dan's panty liners with a continued paycheck. We owe them 30. We are. 10 mil.

Now I ain't a Rocket Scientist (and herein lies the problem cause Dan ain't either) but 10 - 30 is not is feel comfortable with.

Our image is destroyed and Nuance is pissed at Ate.

And thanks Duster for unknowingly onvincing me to sell prior to all this..

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal